2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

Two critical FDA approvals in 2024 included the tumor-agnostic ones of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and repotrectinib (Augtyro), the first of which changed the field for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.^1,2 The latter targeted therapy provided another option for those with an NTRK gene fusion who have experienced disease progression following treatment or have no satisfactory standard therapy and who have metastatic disease or disease where surgical resection is likely to result in severe morbidity.^2-4